MX2016003245A - Calreticulina mutante para la diagnosis de malignidades mieloides. - Google Patents

Calreticulina mutante para la diagnosis de malignidades mieloides.

Info

Publication number
MX2016003245A
MX2016003245A MX2016003245A MX2016003245A MX2016003245A MX 2016003245 A MX2016003245 A MX 2016003245A MX 2016003245 A MX2016003245 A MX 2016003245A MX 2016003245 A MX2016003245 A MX 2016003245A MX 2016003245 A MX2016003245 A MX 2016003245A
Authority
MX
Mexico
Prior art keywords
diagnosis
mutant calreticulin
calreticulin
myeloid malignancies
mutant
Prior art date
Application number
MX2016003245A
Other languages
English (en)
Other versions
MX348980B (es
Inventor
Klampfl Thorsten
Gisslinger Heinz
Kralovics Robert
Original Assignee
Cemm-Forschungszentrum Für Molekulare Medizin Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51795161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016003245(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cemm-Forschungszentrum Für Molekulare Medizin Gmbh filed Critical Cemm-Forschungszentrum Für Molekulare Medizin Gmbh
Publication of MX2016003245A publication Critical patent/MX2016003245A/es
Publication of MX348980B publication Critical patent/MX348980B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La presente invención se refiere a un método para diagnosticar una malignidad mieloide que comprende determinar la presencia de un alelo mutante del gen de calreticulina. También las secuencias genómicas, secuencias de ADNc, secuencias de ARNm y secuencias de proteína de la calreticulina mutante son el objeto de la presente invención. Adicionalmente, la invención se refiere a usos médicos de inhibidores de calreticulina mutante.
MX2016003245A 2013-09-16 2014-09-15 Calreticulina mutante para la diagnosis de malignidades mieloides. MX348980B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13184632 2013-09-16
EP13186939 2013-10-01
US201361909313P 2013-11-26 2013-11-26
PCT/EP2014/069638 WO2015036599A1 (en) 2013-09-16 2014-09-15 Mutant calreticulin for the diagnosis of myeloid malignancies

Publications (2)

Publication Number Publication Date
MX2016003245A true MX2016003245A (es) 2016-09-13
MX348980B MX348980B (es) 2017-07-05

Family

ID=51795161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003245A MX348980B (es) 2013-09-16 2014-09-15 Calreticulina mutante para la diagnosis de malignidades mieloides.

Country Status (16)

Country Link
US (5) US9371570B2 (es)
EP (4) EP3339318A1 (es)
JP (2) JP6745220B2 (es)
KR (1) KR102433548B1 (es)
CN (2) CN113564254A (es)
AU (2) AU2014320262B2 (es)
BR (1) BR112016005611B1 (es)
CA (1) CA2924370C (es)
DK (3) DK2808338T3 (es)
ES (1) ES2577289T3 (es)
MX (1) MX348980B (es)
PL (2) PL2808338T3 (es)
PT (1) PT2808338E (es)
RU (1) RU2668808C2 (es)
SG (1) SG11201601193TA (es)
WO (1) WO2015036599A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3339318A1 (en) 2013-09-16 2018-06-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH Mutant calreticulin for the diagnosis of myeloid malignancies
WO2016077409A1 (en) * 2014-11-12 2016-05-19 Neogenomics Laboratories, Inc. Determining tumor load and biallelic mutation in patients with calr mutation using peripheral blood plasma
WO2016087514A1 (en) * 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
EP3277293A4 (en) * 2015-03-30 2019-01-16 Jeffrey Thomas Loh PROCESS FOR IN VITRO PRODUCTION OF BLOOD PLATES AND COMPOSITIONS AND USES THEREOF
MX2017013623A (es) * 2015-04-23 2018-07-06 Quest Diagnostics Invest Inc Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.
KR101953092B1 (ko) 2015-11-11 2019-06-13 가톨릭대학교 산학협력단 Ｂｃｒ／ａｂｌ 음성 골수증식종양 관련 유전자변이 다중검출용 펩티드핵산 프로브, 이를 포함하는 유전자변이 다중검출 조성물, 다중검출 키트 및 유전자변이 다중검출방법
ITUA20162858A1 (it) * 2016-04-26 2017-10-26 Univ Degli Studi Di Torino Procedimento per la rivelazione di mutazioni di tipo 1 e 2 del gene calreticulina (calr) e relativo kit
AU2017276498A1 (en) * 2016-06-10 2019-01-03 Io Biotech Aps CALR and JAK2 vaccine compositions
CN106566875A (zh) * 2016-09-20 2017-04-19 上海荻硕贝肯医学检验所有限公司 用于检测骨髓异常增生综合征mds基因突变的引物、试剂盒及方法
CN107164474B (zh) * 2017-05-22 2020-09-04 复旦大学附属华山医院 一种检测calr基因2型突变的引物组合物及试剂盒
CN107164473B (zh) * 2017-05-22 2020-08-25 复旦大学附属华山医院 一种检测calr基因1型突变的引物组合物及试剂盒
CN108949971A (zh) * 2017-05-23 2018-12-07 曹国君 钙网蛋白基因1型突变检测用封闭pna探针
CN107462706A (zh) * 2017-08-01 2017-12-12 广西中医药大学附属瑞康医院（广西中西医结合医院） 一种肿瘤试剂盒
CN108434439B (zh) * 2018-01-23 2020-02-07 中国人民解放军总医院 钙网蛋白的医药用途
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
RU2679653C1 (ru) * 2018-08-01 2019-02-12 Общество с ограниченной ответственностью "Формула гена" Набор реактивов для выявления Ph-негативных миелопролиферативных новообразований и способ диагностики на его основе
WO2020084005A1 (en) 2018-10-23 2020-04-30 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin
CN114127113A (zh) * 2019-02-21 2022-03-01 马伦戈治疗公司 与钙网蛋白结合的多功能分子及其用途
CA3130909A1 (en) * 2019-02-28 2020-09-03 Juntendo Educational Foundation Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
US20220282314A1 (en) * 2019-08-30 2022-09-08 Toyo Kohan Co., Ltd. Kit for evaluating a gene mutation related to myeloproliferative neoplasms
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
EP4121081A4 (en) * 2020-03-17 2024-04-17 Memorial Sloan Kettering Cancer Center HETEROCLITE PEPTIDE VACCINES AGAINST CANCER
KR20230057351A (ko) 2020-08-27 2023-04-28 각코우호우진 쥰텐도 항절단형 변이 calr-cd3 이중특이성 항체 및 의약 조성물
WO2023245139A2 (en) * 2022-06-17 2023-12-21 Icahn School Of Medicine At Mount Sinai Mutant calr-peptide based vaccine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20493A (en) * 1858-06-08 Bebtch-plaite
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
WO1997000957A1 (en) 1995-06-23 1997-01-09 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US5846727A (en) * 1996-06-06 1998-12-08 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Microsystem for rapid DNA sequencing
WO1998048003A1 (en) 1997-04-23 1998-10-29 Shriners Hospital For Children Calreticulin-deficient cells
JP2004515209A (ja) * 2000-04-05 2004-05-27 ゲノム セラピューティックス コーポレーション １１ｑ１３．３の高骨量遺伝子
US7205146B1 (en) 2000-06-14 2007-04-17 Oscient Pharmaceuticals Corporation Nucleotide and amino acid sequences relating to respiratory diseases and obesity
US6426220B1 (en) * 2000-10-30 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of calreticulin expression
GB0113266D0 (en) * 2001-05-31 2001-07-25 Bayer Ag Genes and proteins for prevention prediction diagnosis prognosis and treatment of chronic lung disease
WO2006081323A2 (en) 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
CN101616029B (zh) † 2009-07-28 2011-10-26 中兴通讯股份有限公司 一种实现网络拓扑发现的方法及系统
US8841074B2 (en) * 2009-12-04 2014-09-23 Quest Diagnostics Investments Incorporated MPL mutations in JAK2 V617F negative patients with myeloproliferative disease
WO2012088309A1 (en) * 2010-12-21 2012-06-28 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
EP3339318A1 (en) 2013-09-16 2018-06-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH Mutant calreticulin for the diagnosis of myeloid malignancies

Also Published As

Publication number Publication date
AU2019229353A1 (en) 2019-10-03
EP2808338B1 (en) 2016-03-30
BR112016005611A2 (pt) 2017-09-12
RU2668808C2 (ru) 2018-10-02
RU2016114509A3 (es) 2018-03-06
EP3020727B1 (en) 2018-04-04
AU2014320262A1 (en) 2016-03-10
EP3494985A1 (en) 2019-06-12
JP2023024989A (ja) 2023-02-21
US20180251852A1 (en) 2018-09-06
CA2924370C (en) 2024-01-23
AU2019229353B2 (en) 2021-03-18
JP6745220B2 (ja) 2020-08-26
DK3494985T3 (da) 2021-04-19
EP3020727B2 (en) 2021-02-24
US11274350B2 (en) 2022-03-15
MX348980B (es) 2017-07-05
AU2014320262B2 (en) 2019-06-13
CN105916876A (zh) 2016-08-31
DK3020727T3 (en) 2018-07-02
DK2808338T3 (da) 2016-06-06
EP2808338A1 (en) 2014-12-03
JP2016537012A (ja) 2016-12-01
DK3020727T4 (da) 2021-04-19
PL3494985T3 (pl) 2021-08-02
ES2577289T3 (es) 2016-07-14
US9371570B2 (en) 2016-06-21
US10344335B2 (en) 2019-07-09
EP3494985B1 (en) 2021-02-24
SG11201601193TA (en) 2016-04-28
US20220251666A1 (en) 2022-08-11
CN113564254A (zh) 2021-10-29
US20150079091A1 (en) 2015-03-19
RU2016114509A (ru) 2017-10-18
CA2924370A1 (en) 2015-03-19
PL2808338T3 (pl) 2016-09-30
US20200040399A1 (en) 2020-02-06
KR102433548B1 (ko) 2022-08-18
EP3339318A1 (en) 2018-06-27
PT2808338E (pt) 2016-06-15
BR112016005611B1 (pt) 2024-01-16
WO2015036599A1 (en) 2015-03-19
EP3020727A1 (en) 2016-05-18
US20160251723A1 (en) 2016-09-01
KR20160068754A (ko) 2016-06-15

Similar Documents

Publication Publication Date Title
AU2019229353A1 (en) Mutant calreticulin for the diagnosis of myeloid malignancies
MX358117B (es) Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer.
MX357402B (es) Metodo para predecir el pronostico de cancer de mama.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
MX2013005762A (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
MX2015000008A (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
SG10201808585TA (en) Compositions and methods related to diagnosis of prostate cancer
EP3009518A4 (en) Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2016145308A3 (en) Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
MA40636A (fr) Procédés pour détecter le cancer de la prostate
WO2013185779A3 (en) Biomarkers for prostate cancer
TW201612518A (en) Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
WO2015103287A9 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
EP3385717A3 (en) Methods of detecting prostate cancer
MX2014002436A (es) Marcadores de diagnostico.
IN2014DN08312A (es)
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
WO2013173500A3 (en) Method for predicting recurrence of melanoma using mirna alterations
UA95656U (uk) Спосіб прогнозування зрощення перелому
PL410049A1 (pl) Sposób wykrywania zwiększonego ryzyka zachorowania na raka skóry oraz zastosowania genotypowego wariantu genu GRHL3

Legal Events

Date Code Title Description
FG Grant or registration